Digestive Health Institute, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Scand J Gastroenterol. 2020 Nov;55(11):1284-1290. doi: 10.1080/00365521.2020.1821087. Epub 2020 Sep 17.
To determine the association between childhood growth prior to the development of celiac disease (CD) and CD autoimmunity (CDA) identified by periodic serological screening.
The Diabetes Autoimmunity Study in the Young cohort includes 1979 genetically at-risk children from Denver, Colorado, with annual growth measurements from age nine months until ten years. Between 1993 and February 2019, 120 children developed CDA defined by persistent positive tissue transglutaminase autoantibodies (TGA); among these, 71 met our criteria for CD based on histopathological findings or high TGA levels. Age- and sex-specific -scores of weight, body mass index (BMI), and height prior to seroconversion were derived using US reference charts as standards. Joint modeling of serial growth measurements was used to estimate adjusted hazard ratios (aHRs) accounting for celiac-associated human leukocyte antigens, early-life feeding practices, and socio-demographics.
In the first 10 years of life, there were no significant associations between the child's current weight, BMI and height and the risk of screening-detected CDA or CD, neither was the weight nor BMI velocity associated with CDA or CD as identified by screening (all aHRs approximated 1). Increased height velocity was associated with later CD, but not CDA, development (aHR per 0.01- score/year, 1.28; 95% confidence interval [CI] 1.18-1.38 and 1.03; 0.97-1.09, respectively).
In the first 10 years of life, from prospectively collected serial growth measurements, we found no evidence of impaired childhood growth before CD and CDA development as identified through early and periodic screening.
确定在乳糜泻 (CD) 发病前儿童生长情况与通过定期血清学筛查发现的 CD 自身免疫 (CDA) 之间的关联。
糖尿病自身免疫研究中的年轻队列包括 1979 名来自科罗拉多州丹佛市的具有遗传风险的儿童,他们从九个月大到十岁期间每年都进行生长测量。1993 年至 2019 年 2 月期间,共有 120 名儿童通过持续存在阳性组织转谷氨酰胺酶自身抗体 (TGA) 而被诊断为 CDA;其中,71 名儿童根据组织病理学发现或高 TGA 水平符合 CD 的诊断标准。在血清学转换之前,使用美国参考图表作为标准,计算体重、体重指数 (BMI) 和身高的年龄和性别特异性得分。采用序列生长测量联合建模来估计校正后的危险比 (aHR),同时考虑到与乳糜泻相关的人类白细胞抗原、婴儿期喂养方式和社会人口统计学因素。
在生命的前 10 年,儿童当前的体重、BMI 和身高与筛查发现的 CDA 或 CD 风险之间没有显著关联,筛查发现的 CDA 或 CD 也与体重或 BMI 速度无关(所有 aHR 均接近 1)。身高增长速度与后来的 CD 相关,但与 CDA 无关(每增加 0.01 分/年,aHR 分别为 1.28[95%置信区间 (CI) 为 1.18-1.38]和 1.03[0.97-1.09])。
在生命的前 10 年中,我们从前瞻性收集的序列生长测量中发现,在通过早期和定期筛查发现的 CD 和 CDA 发病前,儿童的生长情况没有任何证据表明存在受损。